Pfizer’s African Covid shots plan threatened by low demand

12th May 2022

By: Bloomberg


Font size: - +

Plans to produce Pfizer’s Covid-19 vaccine in Cape Town may be scaled back because of waning demand for the shots, according to the head of the company’s South African manufacturing partner.

About 100 million doses a year are slated to be packaged and filled at a plant controlled by the BioVac Institute, partly owned by the South African government, which would become the first Southern Hemisphere facility to use the messenger RNA technology underlying the Pfizer-BioNTech version.

Yet demand for Covid-19 vaccines has fallen globally as countries start to adapt to the pandemic -- even in Africa where vaccination rates are lowest. Aspen Pharmacare Holdings, the continent’s biggest drugmaker, said this month that it may close a line to make Johnson & Johnson’s dose in South Africa due to a lack of orders.

“As a manufacturer we are concerned about the picture that’s coming through,” Biovac CEO Morena Makhoana said in an interview. “At the rate things are going it will probably be less” than 100-million doses a year.

Biovac has spent about R300-million preparing to make mRNA vaccines and install equipment to keep doses at ultra-cold temperatures. Those upgrades could still be adapted for other shots.

“Certainly for Biovac it’s a big project,” Makhoana said. “Volume wise it’s a step change.”

Biovac is currently processing about four-million doses a year of a pediatric vaccine in South Africa for Sanofi Pasteur and three-million doses of Pfizer’s Prevnar 13 vaccine, a shot given to children to protect against types of pneumococcal bacteria that can cause serious infections.

“It is becoming increasingly recognized that vaccine supply is no longer the primary challenge impacting vaccinating lower and middle income nations,” Pfizer said in a response to questions. “Country readiness is critical is ensuring that a nation is able to effectively receive, transport and administer the vaccine doses as they arrive.”

Makhoana is hopeful that there will be more demand for Pfizer’s Covid-19 vaccine in Africa than for rivals such as the J&J inoculation, especially as Pfizer is seeking to get the dose authorized for children as young as five.

Edited by Bloomberg




From batteries for boats and jet skis, to batteries for cars and quad bikes, SABAT Batteries has positioned itself as the lifestyle battery of...

Weir Minerals Africa and Middle East
Weir Minerals Africa and Middle East

Weir Minerals Europe, Middle East and Africa is a global supplier of excellent minerals solutions, including pumps, valves, hydrocyclones,...


Latest Multimedia

sponsored by

Option 1 (equivalent of R125 a month):

Receive a weekly copy of Creamer Media's Engineering News & Mining Weekly magazine
(print copy for those in South Africa and e-magazine for those outside of South Africa)
Receive daily email newsletters
Access to full search results
Access archive of magazine back copies
Access to Projects in Progress
Access to ONE Research Report of your choice in PDF format

Option 2 (equivalent of R375 a month):

All benefits from Option 1
Access to Creamer Media's Research Channel Africa for ALL Research Reports, in PDF format, on various industrial and mining sectors including Electricity; Water; Energy Transition; Hydrogen; Roads, Rail and Ports; Coal; Gold; Platinum; Battery Metals; etc.

Already a subscriber?

Forgotten your password?







sq:0.423 0.476s - 172pq - 2rq
Subscribe Now